VRC 316/317/320/603 clinical monitoring: POP: 5/1/19 - 3/28/21

Active Awarded Last action

Contract number
75N93019F00132
Awardee
Awarding agency
Obligated
$174,116

Award facts

Opportunity
Contract value 100% obligated
$174,115.89 Current and potential, with all options
Completion date 98% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition after exclusion of sources · 1 offer Multiple Award, Fair Opportunity
Pricing
Cost Plus Fixed Fee
Place of performance
Rockville, MD 20850, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Change Order P00003 · Clinical monitoring initiative (CMI) for VRC 316, 317, 320, 603 $0
Change Order P00002 · Clinical monitoring initiative for VRC 316, 317, 320, 603 $19,803
Change Order P00001 · CMI VRC 316, 317, 320, 630 - the purpose of this modification is to definitize a change order, provide additional funding to cover the costs associated with… $112,091
Original award $42,221

About this award

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $174,115.89 to The Emmes Company, LLC for clinical monitoring services under the Vaccine Research Center (VRC) Clinical Monitoring Initiative. This cost-plus-fixed-fee contract supports clinical monitoring activities for four VRC vaccine trials (VRC 316, 317, 320, and 603) with a period of performance from May 1, 2019 through March 28, 2021. The contract is part of the larger VRC Clinical Monitoring Initiative Indefinite Delivery Vehicle (2017-2024) and was awarded without a set-aside designation, reflecting competitive procurement. The ultimate completion date of December 31, 2026 extends beyond the initial performance period, likely accounting for data analysis and final reporting obligations.

The Emmes Company, LLC, a clinical research organization headquartered in Rockville, Maryland, brings extensive expertise in clinical trial coordination, data management, and regulatory support to this engagement. As a key contractor within the NIAID portfolio, Emmes operates under a comprehensive $545 million research support IDV with the agency and has demonstrated capabilities across multiple NIH institutes. The work will be performed at the company's Potomac, Maryland location, leveraging the organization's established infrastructure for supporting complex biomedical research initiatives and vaccine development programs.

Quick answers

Who was awarded contract 75N93019F00132?

75N93019F00132 was awarded to The Emmes Company, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 30, 2019.

How much is contract 75N93019F00132 worth?

The government has obligated $174,116 on 75N93019F00132.

Is contract 75N93019F00132 an order under another contract?

Yes. 75N93019F00132 is a delivery order under HHSN272201700051I, an indefinite delivery contract, on VRC Clinical Monitoring Initiative 2017-2024.

Was contract 75N93019F00132 competed?

The extent of competition for 75N93019F00132 was full and open competition after exclusion of sources. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award